STOCK TITAN
  1. Home
  2. Sec-filings
  3. AZN
  4. [6-K] ASTRAZENECA PLC Current Report (Foreign Issuer)

AstraZeneca (AZN) adds three fixed-rate US dollar note issues out to 2036

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

AstraZeneca PLC reports the issuance by its subsidiary AstraZeneca Finance LLC of three new U.S. dollar fixed rate note tranches, fully and unconditionally guaranteed by AstraZeneca PLC. These consist of $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036.

The company is furnishing this information so the related underwriting, pricing, officer certificates, and legal opinions can be incorporated into its existing shelf registration statement on Form F-3.

Positive

  • None.

Negative

  • None.

Insights

AstraZeneca adds three tranches of long-dated U.S. dollar debt.

AstraZeneca PLC has supported its financing strategy through AstraZeneca Finance LLC by issuing three series of fixed rate notes: $650,000,000 at 4.000% due 2031, $600,000,000 at 4.300% due 2033, and $750,000,000 at 4.600% due 2036, all guaranteed by the parent.

These maturities extend out to 2036, locking in known interest costs over the medium to long term. The filing also ties these securities to an effective Form F-3 shelf via underwriting and pricing agreements and legal opinions, standard for large issuers accessing U.S. debt markets.

Actual balance sheet impact depends on how this new debt compares with AstraZeneca’s existing borrowings and cash flows, which is not detailed here. Subsequent financial reports will show how interest expense and maturity profiles evolve after these issuances.

Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

 

Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934

 

For the month of March, 2026.

 

Commission File Number: 001-11960

 

AstraZeneca PLC

 

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F: x Form 40-F: ¨

 

 

 

 

 

EXPLANATORY NOTE

 

In connection with the issuance by AstraZeneca Finance LLC of $650,000,000 4.000% Fixed Rate Notes due 2031, $600,000,000 4.300% Fixed Rate Notes due 2033 and $750,000,000 4.600% Fixed Rate Notes due 2036, fully and unconditionally guaranteed by AstraZeneca PLC, AstraZeneca PLC is filing the following documents solely for incorporation into the Registration Statement on Form F-3 (File No. 333-278067):

 

Exhibit List

 

Exhibit No.     Description  
     
1.1   Underwriting Agreement, dated as of February 25. 2026, among AstraZeneca PLC. AstraZeneca Finance LLC and BofA Securities, Inc., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc. and Mizuho Securities USA LLC as representatives of the underwriters.
     
1.2   Pricing Agreement, dated as of February 25, 2026, among AstraZeneca PLC, AstraZeneca Finance LLC and BofA Securities, Inc., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc. and Mizuho Securities USA LLC as representatives of the underwriters.
     
4.1   Officers’ Certificate pursuant to Section 2.08 of the Indenture setting forth the terms of and including forms of the global notes for the $650,000,000 4.000% Fixed Rate Notes due 2031. $600,000,000 4.300% Fixed Rate Notes due 2033 and $750,000,000 4.600% Fixed Rate Notes due 2036.
     
5.1   Opinion of Freshfields LLP.
     
5.2   Opinion of Freshfields US LLP.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ASTRAZENECA PLC
 
Date: March 2, 2026 By: /s/ Matthew Bowden
    Name: Matthew Bowden
    Title: Company Secretary

 

3

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What debt securities did AstraZeneca PLC (AZN) recently issue?

AstraZeneca, via AstraZeneca Finance LLC, issued three fixed rate U.S. dollar notes: $650,000,000 4.000% notes due 2031, $600,000,000 4.300% notes due 2033, and $750,000,000 4.600% notes due 2036, all guaranteed by AstraZeneca PLC.

Who guarantees the new AstraZeneca Finance LLC notes mentioned in the 6-K?

All three note tranches are fully and unconditionally guaranteed by AstraZeneca PLC. This means the parent company stands behind the payment obligations of AstraZeneca Finance LLC for principal and interest on these U.S. dollar fixed rate notes.

What are the interest rates and maturities of AstraZeneca’s new notes?

The issuances include 4.000% Fixed Rate Notes due 2031, 4.300% Fixed Rate Notes due 2033, and 4.600% Fixed Rate Notes due 2036. Each series has a distinct coupon and maturity date, providing a staggered long-term debt profile.

Why is AstraZeneca PLC filing these documents on Form 6-K?

AstraZeneca is furnishing the underwriting agreement, pricing agreement, officer’s certificate, and legal opinions so they can be incorporated into its Form F-3 registration statement. This links the new note issuances to its existing U.S. shelf registration framework.

Which banks underwrote AstraZeneca’s recent U.S. dollar note offerings?

BofA Securities, Inc., Deutsche Bank Securities Inc., HSBC Securities (USA) Inc., and Mizuho Securities USA LLC acted as representatives of the underwriters under the underwriting and pricing agreements dated February 25, 2026, with AstraZeneca PLC and AstraZeneca Finance LLC.

Filing Exhibits & Attachments

5 documents

Other Documents